Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Fujifilm’s Sayonara To Dr. Reddy’s: Deal To Sell Generics In Japan Shelved

This article was originally published in PharmAsia News

Executive Summary

A high-profile joint venture between Fujifilm and Dr. Reddy’s to sell generic drugs in Japan has been terminated only two years after an initial MOU.

You may also be interested in...

After Years Of Partner Search, India's Dr. Reddy's Forms JV With Fujifilm To Tap Japanese Generics Market

MUMBAI - After years of desire to be in the Japanese generics drugs business, Dr. Reddy's Laboratories Ltd. CEO G.V. Prasad reached that milestone in the signing of a memorandum of understanding with Fujifilm Corp. CEO Shigetaka Komori

India, Japan Shake Hands For Faster Entry Of Generics But Market Realities May Be Tougher To Handle

MUMBAI/TOKYO - Introduction of non-discriminatory or national treatment clauses for Indian generic companies in the latest trade agreement between India and Japan will facilitate wider access for Indian generic firms to the world's second-largest pharma market, but analysts predict headwinds await before companies get a real bang for their buck

Fujifilm Focuses On Future Of Generics In Japan

Tokyo-based digital imaging maker Fujifilm is venturing further into the pharmaceutical business with the unveiling of the new Fujifilm Pharma, a generic drug joint venture with Mitsubishi and Toho Holdings. The 80-15-5 joint venture aims to start marketing 200 generic drugs starting in April

Related Content


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts